Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 207-439-9 | CAS number: 471-34-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Bulk calcium carbonate is not considered to be acutely harmful by the oral, dermal or inhalation routes.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 19 November 2007 to 11 December 2007
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 420 (Acute Oral Toxicity - Fixed Dose Method)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 bis (Acute Oral Toxicity - Fixed Dose Procedure)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- fixed dose procedure
- Limit test:
- yes
- Specific details on test material used for the study:
- Bulk calcium carbonate
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (UK) Ltd, Margate, Kent, UK
- Age at study initiation: 8 - 12 weeks
- Weight at study initiation: 205-237 g
- Fasting period before study: overnight prior to dosing
- Housing: suspended polypropylene cages furnished with soft woodflakes and fitted with stainless steel lids.
- Diet: ad libitum (except overnight prior to dosing and 3-4 hours after dosing)
- Water: ad libitum
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 to 25 °C
- Humidity (%): 30 to 70%
- Air changes (per hr): At least 15 changes per hour
- Photoperiod (hrs dark / hrs light): 12 hours of continuous artificial light in each 24 hour period. - Route of administration:
- oral: gavage
- Vehicle:
- arachis oil
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 200 mg/mL
- Amount of vehicle (if gavage): 10 mL/kg - Doses:
- 2000 mg/kg
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: general observations - at 0.5, 1, 2 and 4 hours after dosing then again at least once daily for 14 days; bodyweights were recorded on days 0, 7 and 14.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs. - Statistics:
- No data
- Preliminary study:
- The female test animal did not die during the study following a single oral dose of 2000 mg/kg bw. There were no clinical signs during the preliminary study.
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Sex:
- female
- Dose descriptor:
- LD0
- Effect level:
- > 2 000 mg/kg bw
- Mortality:
- No mortalities occurred.
- Clinical signs:
- other: No clinical signs of systemic toxicity were observed.
- Gross pathology:
- No adverse effects were observed.
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The acute oral median lethal dose (LD50) of the test material in the female Sprague-Dawley rat was estimated to be > 2000 mg/kg bw
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- The study examined whether the bioavailability of calcium carbonate and calcium citrate could be improved by reducing the particle size. Because nanoscale supplements are novel formulas in health foods, the acute toxicity, sub-chronic toxicity (see separate IUCLID entry) and bioavailability (see separate IUCLID entry) needs to be determined in both sexes of mice in advance.
Standard acute toxicological evaluations of the ICR mice were performed in the initial assessment of the effects of nanoscale calcium carbonate internalisation. Micro calcium carbonate and nano calcium carbonate were administered in a single dose by gavage using a gastric intubation tube. The animals were then observed for a period of 7 days. - GLP compliance:
- no
- Specific details on test material used for the study:
- Uncoated nano calcium carbonate
- Species:
- mouse
- Strain:
- ICR
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: National Taiwan University Hospital, Taipei, Taiwan
- Age at study initiation: 8-10 weeks
- Fasting period before study: Animals were fasted overnight
- Diet: Pelleted mouse feed available ad libitum
- Water: Reverse osmosis water available ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21-25 °C
- Humidity (%): 30-70%
- Photoperiod (hrs dark / hrs light): 12 h/12 h day/night cycle
Sham surgery (n = 6, SHAM) or bilateral ovariectomy (n = 30, OVX) was performed from a dorsal approach at 6 to 8 week old mice. Surgical removal of the ovaries is a well-represented approach to mimic the postmenopausal condition in mice. In the sham operation, ovaries were exteriorised and then replaced. - Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- The test materials were administered in a single dose by gavage using a gastric intubation tube.
- Doses:
- Vitamin D3 (261 U/ kg bw) plus micro calcium carbonate: 1.3g/kg bw
Vitamin D3 (261 U/ kg bw) plus nano calcium carbonate: 1.3g/kg bw - No. of animals per sex per dose:
- 8 animals/sex/dose
- Control animals:
- yes
- Details on study design:
- On day seven, all the animals were weighed and any signs of toxicity were noted.
- Sex:
- male/female
- Dose descriptor:
- other: NOAEL
- Effect level:
- 1 300 mg/kg bw
- Mortality:
- No mortality was observed.
- Clinical signs:
- other: Throughout the study, no unusual behaviour or differences between groups were observed (i.e. no laboured breathing, difficulty moving, hunching or unusual interactions with cage mates were observed).
- Conclusions:
- No mortality or unusual behaviour were observed during the course of the study. The NOAEL for both micro calcium carbonate and nano calcium carbonate were reported to be 1.3 g/kg bw.
Referenceopen allclose all
Table 1: Body weight and mortality during the 7-day acute toxicity test
Dose |
Sex (n) |
Initial body weight (g) |
Final body weight (g) |
Mortality dead/treated |
Control |
Male (8) Female (8) |
33.2 ± 3.3 32.5 ± 3.7 |
35.3 ± 3.9 34.2 ± 3.8 |
0/8 0/8 |
Micro calcium carbonate (1.3 g/kg bw) |
Male (8) Female (8) |
33.4 ± 3.2 32.7 ± 3.4 |
34.9 ± 3.2 34.3 ± 3.6 |
0/8 0/8 |
Nano calcium carbonate (1.3 g/kg bw) |
Male (8) Female (8) |
32.5 ± 3.6 33.1 ± 2.9 |
33.7 ± 4.1 34.9 ±3.8 |
0/8 0/8 |
Data are mean ± SE values
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- Two studies available, both reliable (K=1, K=2)
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 20 April 2010 to 04 May 2010
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 403 (Acute Inhalation Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.2 (Acute Toxicity (Inhalation))
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1300 (Acute inhalation toxicity)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
- Specific details on test material used for the study:
- Bulk calcium carbonate
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Laboratories B.V., Kreuzelweg 53, 5961 NM Horst, Netherlands
- Age at study initiation: 9 weeks
- Weight at study initiation: Males: 254.7 - 271.5 g; Females: 177.3 - 200.3 g
- Housing: Optimal Hygienic Conditions (OHC) inside a barrier system. Animals were housed in groups of 5 of the same sex in Makrolon® type-IV cages with wire mesh tops and standard softwood bedding including paper enrichment.
- Diet: Pelleted standard Harlan Teklad 2914C rat maintenance diet available ad libitum except during the period when the animals were restrained in exposure tubes.
- Water: Community tap water from Füllinsdorf available ad libitum in water bottles, except during the period when they were restrained in exposure tubes.
- Acclimation period: Seven days under laboratory conditions
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3 °C
- Humidity (%): 30 - 70%
- Air changes: 10-15 per hour
- Photoperiod: 12 hour fluorescent light / 12 hour dark cycle - Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- nose only
- Remarks:
- Flow past exposure
- Vehicle:
- air
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: Inhalation exposure was performed using a flow-past, nose-only exposure system. The inhalation exposure system is located inside a ducted extraction cabinet.
- Exposure chamber volume: Not specified
- Method of holding animals in test chamber: The animals were confined separately in restraint tubes which were positioned radially around the exposure chamber.
- Source and rate of air: The flow of air at each tube was 0.97 L/min, which is sufficient to minimize re-breathing of the test aerosol as it is more than twice the respiratory minute volume of rodents. The actual airflow rate through the exposure chamber was recorded at approximately 30 minute intervals from the start of the inhalation exposure.
- Method of conditioning air: Not specified
- System of generating particulates/aerosols: A dust aerosol was generated from the test item using a CR3020 rotating brush aerosol generator connected to a micronizing jet mill. The aerosol generated was then discharged into the exposure chamber through a 63Ni charge neutralizer.
- Method of particle size determination: The particle size distribution of the test aerosol was determined three times during exposure using a 7 stage Mercer cascade Impactor. The particle size distribution was measured by gravimetrically analyzing the test item deposited on each stage of the cascade impactor.
Mass Median Aerodynamic Diameters (MMAD) and Geometric Standard Deviations (GSD) were calculated on the basis of the results from the impactor, using Microsoft Excel Software. The target range was 1 to 4 μm for the MMAD and between 1.5 and 3 for the GSD.
- Treatment of exhaust air: The exhaled air is exhausted through the gap near each feed tube out of the exposure chamber.
- Temperature, humidity, pressure etc in air chamber: The oxygen concentration, airflow rate, temperature and relative humidity of the test atmosphere was measured continuously during exposure using a calibrated device. The results were recorded manually and were reported at 30 minute intervals from the start of exposure and additionally at the end of exposure. The oxygen concentration was maintained above 19% during each exposure period.
Mean oxygen concentration: 20.9 vol%, Mean temperature: 22.4 °C; Mean relative humidity: 7.3%
TEST ATMOSPHERE
- Brief description of analytical method used:
Gravimetric determinations of aerosol concentration were performed eight times during exposure. The samples were collected on a Millipore®durapore filter, Type HVLP loaded in a 47 mm inline stainless steel filter sampling device. The filters were weighed before and immediately after sampling using a calibrated balance. The test aerosol concentration was calculated from the amount of test item present on the filter and the sample volume.
Chemical determinations of aerosol concentration were performed eight times during exposure using the filters collected for gravimetric determination. The filters were transferred into appropriate labeled vials, forwarded at ambient temperature the scientist responsible for formulation analysis and stored at room temperature (20 ± 5 °C) until analysis. The samples were analyzed using an AAS method as follows:
Instrument: Perkin-Elmer Model PE 2100 (software 4100) atomic absorption spectrometer
Flame: Acetylene flame/nitrogen(I) oxide
Slit Width: 0.7 nm high
Wavelength: Calcium: 422.7 nm
- Samples taken from breathing zone: yes
TEST ATMOSPHERE
- Particle size distribution: See table; the particle size of the generated aerosol was fairly stable during the whole exposure period.
- MMAD (Mass median aerodynamic diameter) / GSD (Geometric st. dev.): The Mass Median Aerodynamic Diameters (MMAD) obtained from three gravimetric measurements of particle size distribution during the exposure were similar (MMAD between 2.28 μm and 2.89 μm).The MMADs were well within the target range of 1 to 4 μm, thus deposition of the particles can be assumed to have occurred in both the upper and the lower respiratory tract. In addition, the Geometric Standard Deviations (GSD) were within the target range of 1.5 to 3. Hence, the particle size distributions obtained were considered to be appropriate for acute inhalation toxicity testing. - Analytical verification of test atmosphere concentrations:
- yes
- Remarks:
- Atomic absorption spectrometry
- Duration of exposure:
- 4 h
- Remarks on duration:
- Exposure was interrupted three times for a total of 8 minutes for cleaning purpose. Nevertheless, the animals were exposed for a period of 4 hours as those interruptions were accounted for.
- Concentrations:
- Target aerosol concentration: 5 mg/L air
Nominal aerosol concentration: 9.4 mg/L air
Mean measured gravimetric aerosol concentration: 3.0 mg/L air
Mean measured chemical aerosol concentration: 3.0 mg/L air
It was not possible to achieve the target concentration of 5 mg/L air as the achieved level was at the technical limit. Therefore, some variations in the aerosol concentrations occurred. The chemical aerosol concentration compared favourably to the gravimetrically determined concentration. This was in accordance with the high purity of the test item. - No. of animals per sex per dose:
- 5 animals/ sex
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Observations for viability were recorded once before exposure on the day of exposure (test day 1), three times during exposure, immediately and 1 h after exposure on test day 1 and twice daily during the observation period.
- Necropsy of survivors performed: yes: All animals were necropsied and examined for macroscopic abnormalities.
- Other examinations performed: Clinical signs: Each animal was examined three times during exposure, immediately and 1 h after exposure on test day 1 and once daily during the observation period. Only grossly abnormal signs were detectable during exposure, as the animals were restrained in the exposure tubes; Body weight: The body weight of each animal was recorded on test days 1 (before exposure), 2, 4, 8 and 15 (before necropsy). - Statistics:
- No statistical analysis was performed as only one group was allocated to the study.
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- > 3 mg/L air (analytical)
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Mortality:
- All animals survived the scheduled observation period.
- Clinical signs:
- other: Clinical signs consisted of ruffled fur only and were recorded for all animals starting one hour after exposure. This observation was noted for up to a maximum of test day 4. From test day 5 onwards all animals were free of clinical signs.
- Body weight:
- The body weight of animal No. 1 on test day 1 was considered to be incorrect, probably due to a weighing error. The body weight of this animal from test day 2 onwards was within the range of the other male animals. These animals showed slight body weight loss from test day 1 to test day 2. Marginal to slight body weight loss was also noted in three females from test day 1 to test day 2 and in one female up to test day 4. All these animals showed normal body weight thereafter as well as the remaining female animal.
- Gross pathology:
- There were no macroscopic findings during this study.
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The LC50 of Calcium carbonate (CAS: 471-34-1) obtained in this study was estimated to be greater than 3.0 mg/L air (chemically determined mean aerosol concentration). This was the highest technically achievable concentration and in accordance with Regulation (EC) No. 1272/2008 (EU CLP) the substance is not considered to be classified.
Reference
Table 1: Test atmosphere conditions
Recording time (hours:min) |
O2 concentration (vol %) |
Temperature (° C) |
Relative humidity (% RH) |
||||
08:10 |
20.7 |
22.5 |
6.4 |
||||
08:40 |
20.6 |
22.5 |
6.2 |
||||
09:10 |
20.7 |
22.5 |
6.7 |
||||
09:45 |
20.6 |
22.5 |
13.8 |
||||
10:15 |
20.7 |
22.5 |
7.7 |
||||
10:45 |
20.7 |
22.6 |
6.7 |
||||
11:15 |
20.7 |
22.5 |
6.2 |
||||
11:45 |
20.6 |
22.3 |
6.0 |
||||
12:15 |
20.7 |
22.3 |
6.8 |
||||
12.18 |
20.7 |
22.2 |
6.8 |
||||
MEAN |
20.6 |
22.4 |
7.3 |
||||
St. Dev. |
0.0 |
0.1 |
2.3 |
||||
N |
10 |
10 |
10 |
Table 2: Chemical determination of aerosol concentrations
Sampling time (hours:min) |
Sampling volume (L) |
Amount of test item on the filter (mg) |
Chemical aerosol concentration (mg/L air) |
08:25-08:30 |
5.1 |
29.49 |
5.8 |
09:25 - 09:30 |
5.1 |
10.84 |
2.1 |
09:44 - 09:48 |
4.0 |
5.799 |
1.4 |
10:03 - 10:07 |
4.0 |
7.885 |
2.0 |
10:25 - 10:29 |
4.0 |
14.14 |
3.5 |
10:56 - 11:00 |
4.0 |
11.90 |
2.9 |
11:30 - 11:34 |
4.0 |
13.11 |
3.2 |
11:55 - 11:59 |
4.0 |
12.37 |
3.1 |
Mean |
3.0 |
||
St. Dev. |
1.3 |
||
N |
8 |
Table 3: Particle size distribution
Time |
Total amount collected (µg) |
Percentages: Stage No. Effective cut-off diameter (µm) |
MMAD (µm) |
GSD |
Corr. Coeff. (R) |
%<4 µm |
|||||||
1 -- |
2 4.6 |
3 3.0 |
4 2.13 |
5 1.6 |
6 1.06 |
7 0.715 |
8 0.325 |
||||||
08:36 |
754 |
15.4 |
25.6 |
27.1 |
17.4 |
8.0 |
3.6 |
1.1 |
2.0 |
2.61 |
2.11 |
0.946 |
71.6 |
10:32 |
849 |
22.0 |
26.3 |
19.4 |
15.4 |
9.2 |
3.2 |
2.5 |
2.0 |
2.89 |
2.37 |
0.965 |
64.7 |
11:37 |
735 |
6.9 |
34.3 |
25.9 |
16.2 |
11.2 |
2.3 |
0.3 |
3.0 |
2.28 |
1.94 |
0.913 |
80.2 |
Table 4: Body weights
Day |
Animal body weight (g) |
||||
1 |
2 |
3 |
4 |
5 |
|
Males |
|||||
1 |
140.7a |
264.6 |
271.5 |
268.9 |
254.7 |
2 |
255.7 |
252.5 |
264.7 |
262.1 |
243.3 |
4 |
264.8 |
262.2 |
271.9 |
270.7 |
254.7 |
8 |
283.3 |
279.8 |
282.5 |
286.3 |
266.5 |
15 |
305.8 |
300.5 |
306.1 |
310.2 |
282.2 |
Females |
|||||
1 |
200.3 |
194.0 |
199.0 |
177.3 |
194.9 |
2 |
198.6 |
189.8 |
195.6 |
185.6 |
189.5 |
4 |
203.9 |
197.0 |
194.7 |
193.3 |
197.0 |
8 |
214.3 |
205.7 |
205.9 |
196.5 |
209.5 |
15 |
214.6 |
213.0 |
221.4 |
209.3 |
226.5 |
a Error undetermined
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating conc.
- Value:
- 3 000 mg/m³ air
- Quality of whole database:
- One study available, K=1
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 06 January 2010 - 20 January 2010
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
- Specific details on test material used for the study:
- Uncoated nano calcium carbonate
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Laboratories UK Limited, Bicester, Oxon, UK
- Age at study initiation: 8-12 weeks
- Weight at study initiation: at least 200 g
- Fasting period before study: No data
- Housing: The animals were housed in suspended solid floor polypropylene cages furnished with woodflakes. The animals were housed individually during the 24-hour exposure period and in groups of five, by sex, for the remainder of the study.
- Diet (e.g. ad libitum): Food (2014 Teklad Global Rodent diet) was available ad libitum.
- Water (e.g. ad libitum): Mains drinking water was available ad libitum.
- Acclimation period: At least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19-25 °C
- Humidity (%): 30-70%
- Air changes (per hr): at least fifteen changes per hour
- Photoperiod (hrs dark / hrs light): twelve hours continuous light (06:00 to 18:00) and twelve hours darkness - Type of coverage:
- semiocclusive
- Vehicle:
- arachis oil
- Details on dermal exposure:
- TEST SITE
- Area of exposure: back and flanks of each animal
- % coverage: approximately 10% of the total body surface area
- Type of wrap if used: A piece of surgical gauze was placed over the treatment area and semi-occluded with a piece of self-adhesive bandage.
REMOVAL OF TEST SUBSTANCE
- Washing (if done): After the 24-hour contact period the bandage was carefully removed and the treated skin and surrounding hair wiped with cotton wool moistened with arachis oil BP to remove any residual test material.
- Time after start of exposure: 24 h
TEST MATERIAL
The appropriate amount of test material, moistened with arachis oil BP, was applied as evenly as possible to an area of shorn skin using a graduated syringe. - Duration of exposure:
- 24 h
- Doses:
- 2000 mg/kg
- No. of animals per sex per dose:
- 5 animals/ sex/ dose
- Control animals:
- not specified
- Details on study design:
- The animals were observed for deaths or overt signs of toxicity 0.5, 1, 2 and 4 hours after dosing and subsequently once daily for fourteen days.
After removal of the dressings and subsequently once daily for fourteen days, the test sites were examined for evidence of primary irritation and scored according to the scale from Draize (1977).
Individual bodyweights were recorded prior to application of the test material on Day 0 and on Days 7 and 14.
At the end of the study the animals were killed by cervical dislocation. All animals were subjected to gross necropsy. This consisted of an external examination and opening of the abdominal and thoracic cavities. The appearance of any macroscopic abnormalities was recorded. No tissues were retained. - Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Mortality:
- There were no deaths.
- Clinical signs:
- other: There were no signs of systemic toxicity or dermal irritation.
- Gross pathology:
- No abnormalities were noted at necropsy.
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The acute dermal median lethal dose (LD50) of the test material in the Wistar strain rat was found to be greater than 2000 mg/kg bodyweight.
Reference
Table 1: Individual clinical observations and mortality data
Dose level (mg/kg) |
Animal no. & sex |
Effects noted after initiation of exposure (hours) |
Effects noted after initiation of exposure (days) |
||||||||||||||||
0.5 |
1 |
2 |
4 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
||
2000 |
Males (1-1, 1-2, 1-3 & 1-4) |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Females (2-1, 2-2, 2-3 & 2-4) |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 = no signs of systemic toxicity
Table 2: Individual dermal reactions – Males
Dose level (mg/kg) |
Animal no. & sex |
Observation |
Effects noted after initiation of exposure (days) |
|||||||||||||
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
|||
2000 |
Males (1-1, 1-2, 1-3 & 1-4) |
Erythema |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Oedema |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
Other |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 = No reactions
Table 3: Individual dermal reactions – Females
Dose level (mg/kg) |
Animal no. & sex |
Observation |
Effects noted after initiation of exposure (days) |
|||||||||||||
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
|||
2000 |
Females (2-1, 2-2, 2-3 & 2-4) |
Erythema |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Oedema |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
Other |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 = No reactions
Table 4: Individual bodyweights and weekly bodyweight changes
Dose level (mg/kg) |
Animal no. & sex |
Bodyweight (g) at Day |
Bodyweight change (g) during week |
|||
0 |
7 |
14 |
1 |
2 |
||
2000 |
1-0 Male |
232 |
256 |
278 |
24 |
22 |
1-1 Male |
235 |
255 |
270 |
20 |
15 |
|
1-2 Male |
242 |
268 |
288 |
26 |
20 |
|
1-3 Male |
224 |
246 |
270 |
22 |
24 |
|
1-4 Male |
234 |
261 |
279 |
27 |
18 |
|
2-0 Female |
220 |
228 |
239 |
8 |
11 |
|
2-1 Female |
203 |
204 |
216 |
1 |
12 |
|
2-2 Female |
211 |
216 |
218 |
5 |
2 |
|
2-3 Female |
217 |
220 |
230 |
3 |
10 |
|
2-4 Female |
212 |
213 |
220 |
1 |
7 |
Table 5: Individual necropsy findings
Dose level (mg/kg) |
Animal no. & sex |
Macroscopic observations |
2000 |
Males (1-1, 1-2, 1-3 & 1-4) |
No abnormalities detected |
Females (2-1, 2-2, 2-3 & 2-4) |
No abnormalities detected |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- One study available, K=1
Additional information
Acute toxicity - Oral route:
In a reliable GLP study performed to OECD Guideline 420 [Bradshaw 2008] bulk calcium carbonate was administered by gavage at 2,000 mg/kg bw to 5 female rats (Sprague-Dawley). The animals were observed for clinical signs and mortality for 14 days. No mortalities were observed in the observation period and there were no clinical signs of systemic toxicity, adverse changes in bodyweight or macroscopic effects noted at necropsy. The oral LD50 for rats was > 2000 mg/kg bw.
Acute toxicity - Inhalation route:
In a reliable GLP study performed to OECD Guideline 403 [Schuler D, 2010], bulk calcium carbonate was administered by inhalation at a measured concentration of 3 mg/L air to 5 male and 5 female rats (Wistar). The animals were observed for clinical signs and mortality for 14 days and on test day 15, all animals were sacrificed and necropsied.All animals survived the scheduled observation period. Ruffled fur was observed in all animals from the end of the exposure up to test day 4. Thereafter, all animals were free of clinical signs. Transient body weight loss was noted in most animals from test day 1 to test day 2 but normal body weight development was observed in general thereafter. No macroscopic findings were present at necropsy.The inhalation LD50 for rats was > 3 mg/L air. This was the highest technically achievable concentration.
Three different samples of Calcium Carbonate were supplied by the Sponsor: 1). calcium carbonate (nano); 2). calcium carbonate (aragonite form); 3). precipitated calcium carbonate (bulk). Preliminary technical trials were conducted with the above-mentioned samples differing in size (nano versus precipitated) and crystal structure (aragonite versus precipitated).
The original intention was to use the nano form of calcium carbonate because this form was anticipated to represent the worst case as it is likely to be more soluble than the bulk form due to the smaller particle size and hence greater surface area for systemic absorption and passage throughout the lungs. However, the aerosol concentration targeted in this study could only be achieved with precipitated calcium carbonate. Aerosol generation trials with calcium carbonate (nano) and calcium carbonate (aragonite form) resulted in blockage of the aerosol generator. As a result the study was performed with precipitated calcium carbonate (bulk).
Acute toxicity - Dermal route:
In a reliable GLP study performed to OECD Guideline 402 [Bradshaw 2010] uncoated nano calcium carbonate was applied as a paste in arachis oil to the skin of 5 male and 5 female rats (Wistar) at a dose of 2000 mg/kg bw and covered with a semi-occlusive dressing for 24 hours. After completion of the exposure period the skin was wiped with cotton wool moistened with arachis oil to remove any residual test material. There were no deaths or clinical signs of systemic toxicity during the 14 -day observation period. All animals showed expected bodyweight gains over the study period. No abnormalities were noted at necropsy. The LD50was > 2000 mg/kg bw.
The nano
form of calcium carbonate was tested because this form was anticipated
to represent the worst case as the smaller size particles are more
likely to be transported through the skin. However, the results are
directly applicable to the bulk form of calcium carbonate.
Justification for classification or non-classification
Oral: The oral LD50 for rats was > 2000 mg/kg bw in an OECD Guideline 420 study. Therefore bulk calcium carbonate does not require classification according to the criteria described in Regulation (EC) No 1272/2008
Inhalation: The inhalation LD50 for rats was > 3 mg/L air in an OECD Guideline 403 study. The result was achieved at the maximum attainable concentration and is considered to be equivalent to a limit test conducted at 5 mg/L. Therefore, bulk calcium carbonate is not considered to be classified according to the criteria described in Regulation (EC) No 1272/2008.
Dermal: The dermal LD50 for rats was > 2000 mg/kg bw in an OECD Guideline 402 study performed using uncoated nano calcium carbonate. This result is read across to the bulk form, therefore bulk calcium carbonate does not require classification according to the criteria described in Regulation (EC) No 1272/2008
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.